|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-1-3
|
|
pubmed:abstractText |
Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1539-3704
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
2
|
|
pubmed:volume |
146
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-33
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17200219-Antibodies, Monoclonal,
pubmed-meshheading:17200219-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17200219-Antigens, CD20,
pubmed-meshheading:17200219-Drug Administration Schedule,
pubmed-meshheading:17200219-Humans,
pubmed-meshheading:17200219-Immunologic Factors,
pubmed-meshheading:17200219-Platelet Count,
pubmed-meshheading:17200219-Purpura, Thrombocytopenic, Idiopathic,
pubmed-meshheading:17200219-Research Design
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
|
|
pubmed:affiliation |
McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada. arnold@mcmaster.ca
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
